Kathryn A. Bylow, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Breast Care Center - Cancer Center - Froedtert Hospital

Specialties

Geriatric Medicine
Medical Oncology

Languages

English

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Kathryn Bylow, MD, is Associate Professor of Medicine in the Division of Hematology and Oncology, specializing in genitourinary malignancies (prostate cancer, kidney cancer, bladder cancer and testicular cancer). She also has expertise in caring for older cancer patients and is Board certified in both medical oncology and geriatrics.

A native of Milwaukee, Dr. Bylow received her medical degree from the University of Wisconsin-Madison in 2000 and went on to obtain her internal medicine residency training at Vanderbilt University. She completed her fellowship training in both medical oncology and geriatrics at the University of Chicago during which time she received the American Society of Clinical Oncology Young Investigator Award for her work studying the link between prostate cancer treatment and the development of frailty in older men.

Research Interests

Her current research interests include investigator-initiated research evaluating treatment-related toxicities in older men with prostate cancer. She is also the principal investigator of several clinical trials evaluating the use of novel drugs in prostate, kidney, and bladder cancer.

Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

(Atallah E, Bylow K, Troy J, Saber W.) Curr Hematol Malig Rep. 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643 SCOPUS ID: 2-s2.0-84896710555 01/09/2014
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

(Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M.) Cancer. 2014 Mar 01;120(5):692-701 PMID: 24249435 SCOPUS ID: 2-s2.0-84896703767 11/20/2013
The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study.

(Ramsdale E, Polite B, Hemmerich J, Bylow K, Kindler HL, Mohile S, Dale W.) J Am Geriatr Soc. 2013 Nov;61(11):2043-4 PMID: 24219208 SCOPUS ID: 2-s2.0-84887505934 11/14/2013
Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.

(Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W.) Urology. 2011 Apr;77(4):934-40 PMID: 21269665 PMCID: PMC3074039 SCOPUS ID: 2-s2.0-79953849203 01/29/2011
Management of complications of androgen deprivation therapy in the older man.

(Mohile SG, Mustian K, Bylow K, Hall W, Dale W.) Crit Rev Oncol Hematol. 2009 Jun;70(3):235-55 PMID: 18952456 PMCID: PMC3074615 SCOPUS ID: 2-s2.0-67349141307 10/28/2008
WITHDRAWN: Cognitive effects of androgen deprivation therapy in an older cohort of men with prostrate cancer.

(Mohile SG et al..) Crit Rev Oncol Hematol. 2009 May 14: PMID: 19446466 05/19/2009
Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.

(Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM.) J Clin Oncol. 2009 Apr 01;27(10):1557-63 PMID: 19255325 PMCID: PMC2738613 SCOPUS ID: 2-s2.0-63749112245 03/04/2009
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.

(Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF.) Clin Genitourin Cancer. 2009 Jan;7(1):39-42 PMID: 19213667 SCOPUS ID: 2-s2.0-65249089759 02/14/2009
Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.

(Bylow K, Dale W, Mustian K, Stadler WM, Rodin M, Hall W, Lachs M, Mohile SG.) Urology. 2008 Aug;72(2):422-7 PMID: 18561991 PMCID: PMC3032402 SCOPUS ID: 2-s2.0-48349102661 06/20/2008
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.

(Bylow K, Mohile SG, Stadler WM, Dale W.) Cancer. 2007 Dec 15;110(12):2604-13 PMID: 17960609 SCOPUS ID: 2-s2.0-37049038470 10/26/2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

(Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.) BJU Int. 2007 Jul;100(1):70-5 PMID: 17552955 SCOPUS ID: 2-s2.0-34249950226 06/08/2007
A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.

(Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M.) Cancer. 2007 Feb 15;109(4):802-10 PMID: 17219443 SCOPUS ID: 2-s2.0-33846905273 01/16/2007